AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05413642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended treatment schedule
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
Study NCT05413642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment regimens different from the recommended one according to family physician personal practice
Study NCT06535568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon
Description: Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
Study NCT06535568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Essential pro (iVascular, Barceona, Spain) paclitaxel eluting coronary balloon dilatation catheter is a rapid exchange catheter, also known as RX because it has a proximal simple lumen configuration and a distal coaxial dual lumen, intended for coronary arteries percutaneous transluminal angioplasties. Patients assigned to this Arm will be treated with a Drug-Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care.
Study NCT06535568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single antiplatelet therapy (SAPT)
Description: The antithrombotic regimen is single antiplatelet therapy (SAPT). The Investigator will decide if to use aspirin or clopidogrel, whereas ticagrelor or prasugrel are not recommended in our study population since no benefit (or even harm) has been shown by these drugs in head-to-head trials versus clopidogrel in elderly PCI populations. The type of agent and treatment duration will be selected according to the clinical characteristics of the patient.
Study NCT06535568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT)
Description: The antithrombotic regimen will follow the standard of care with a dual antiplatelet regimen (DAPT) per local preferences and international guidelines/ARC consensus paper. The type of agent and treatment duration will be selected according to the patient's clinical characteristics.
Study NCT05201001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Study NCT05593991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated heels
Description: Each subject will undergo the following evaluations:~1. neutral barefoot position;~2. neutral barefoot position (re-test);~3. 3 cm rise of both heels, made with plastic spacer;~4. 7 cm rise of both heels, made with plastic spacer.
Study NCT00889096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
Study NCT00889096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
Study NCT05238584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial omentectomy
Description: Partial omentectomy: with preservation of the greater omentum at >2 cm from the gastroepiploic arcade.
Study NCT05426356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Intervention
Description: Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
Study NCT05426356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgical Management
Description: Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
Study NCT05970653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
Study NCT05970653 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study NCT05201001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APX005M
Description: adding immunotherapy with or without radiation therapy to chemotherapy. Low dose radiation therapy is to sensitise tumour cells to immunotherapy.
Study NCT06380023 — intervention group
Intervention type: DEVICE
Intervention: Enclosure barrier
Description: Surgical mask \& Enclosure tent compared with open suction
Study NCT06561737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: For the students in the experimental group, the application was first demonstrated on a model by the course instructor, after which each student was required to perform the application individually. While the students were performing the application, someone not part of the research team recorded them on their phones. During the application, two researchers independently assessed the student's skills using the application checklist. Afterward, the students were asked to watch their videos and evaluate themselves over a 15-day period. After 15 days, the students were called back and asked to perform the same application again. At this stage, the researchers once again evaluated the students independently.
Study NCT05330949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence Tomography Angiography, Uterine artry doppler
Description: vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters
Study NCT05124626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIRPE with two bars
Description: Minimally invasive repair of pectus excavatum utilizing two metallic bars
Study NCT06554236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy and sensory training
Description: Physical therapy standard of care and 5 minutes of sensory training.
Study NCT05504772 — intervention group
Intervention type: GENETIC
Intervention: RNA seq
Description: Results will be used for bioinformatics analysis for fusion transcripts and gene expression.
Study NCT05124626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIRPE with one bar
Description: Minimally invasive repair of pectus excavatum utilizing one metallic bar
Study NCT05555550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluciclovine
Description: 18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
Study NCT04847544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: ADX-629 administered orally twice daily (BID) for up to 28 days.
Study NCT04847544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally BID for up to 28 days.
Study NCT05504772 — intervention group
Intervention type: GENETIC
Intervention: DNA Methylation
Description: Genome-wide assessment of DNA methylation will be conducted on all samples where possible.
Study NCT06329050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Administration of Losartan tablets(50 mg)
Study NCT06329050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo tablets
Study NCT05200793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
Study NCT05200793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 10 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
Study NCT05200793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg
Description: This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
Study NCT04325503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa
Description: carbidopa and carbidopa-levodopa standard treatment
Study NCT03467906 — intervention group
Intervention type: OTHER
Intervention: In-laboratory assessment
Description: Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
Study NCT04766866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation
Description: A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
Study NCT05991024 — intervention group
Intervention type: BEHAVIORAL
Intervention: the incisional hernia recurrent
Description: Recurrence after repair was the main outcome
Study NCT05134220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Calcium
Description: * Serum calcium level.~* Serum phosphorus level. will be measured to all study population
Study NCT05565053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral thoracal erector spinae plane block
Description: Bilateral upper thoracal erector spinae plane block with ultrasound
Study NCT05565053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapezius muscle trigger point injection
Description: Trapezius muscle trigger point injection
Study NCT05079425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXC736
Description: Oral administration
Study NCT05079425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral administration
Study NCT05033743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole 2 GM Oral Granules
Description: Once weekly 2g oral secnidazole for 18 weeks
Study NCT05504772 — intervention group
Intervention type: GENETIC
Intervention: Targeted Panel Sequencing
Description: Targeted panel sequencing may be performed:~1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available~2. When mosaicism is suspected~3. When indicated for a disease type
Study NCT06223893 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CirrhoCare management system
Description: This is a UKCA-marked, digital-therapeutic system consisting of:~* clinical-grade, cirrhosis monitoring sensors and a smartphone app,~* a clinical team-facing, decision-facilitating dashboard, and~* CyberLiver's platform incorporating hepatic algorithms.~The CirrhoCare kit consists of: - Apple watch - iPhone with an in-built CirrhoCare app - a digital Bluetooth-linked system comprised of: \~Wellue BP monitor, \~Wellue weighing scale \~Bluetooth thermometer.~The CirrhoCare management system also includes:~* The clinician dashboard: All participant data collected through the app will be reviewed by the clinical team via the clinician dashboard.~* The CirrhoCare algorithm: This algorithm will advise the clinical team if the participant is at high, medium, or low risk of developing a particular outcome event, based on monitoring data collected each day from the participant which is compared to the baseline values and average values collected over the first week of monitoring.
Study NCT04826874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect labeling
Description: Short behavioral intervention teaching affect labeling
Study NCT05194319 — intervention group
Intervention type: OTHER
Intervention: All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)
Description: The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
Study NCT06518291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG
Description: Comparing two drugs in UTI treatment
Study NCT04965454 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluorine-18 fluorocholine
Description: 18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
Study NCT04808648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: tablet, oral, 200 mg once daily for day 1 and day 12
Study NCT04808648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: capsule, oral, 200 mg twice daily for day 8 to day 14
Study NCT04808648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: capsule, oral, 600 mg once daily for day 8 to day 16
Study NCT05006053 — intervention group
Intervention type: OTHER
Intervention: Interviews/Focus groups
Description: Qualitative study (no intervention delivered)
Study NCT05207761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D565
Description: Q.D. in both eye
Study NCT05207761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930
Description: T.I.D in both eye
Study NCT05504772 — intervention group
Intervention type: GENETIC
Intervention: High Throughput Sequencing (in vitro)
Description: High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.
Study NCT05504772 — intervention group
Intervention type: GENETIC
Intervention: Patient Derived Xenograft (PDX)(in vivo)
Description: In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.
Study NCT05504772 — intervention group
Intervention type: OTHER
Intervention: Liquid Biopsy
Description: Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.
Study NCT06518291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: treatment of UTI
Study NCT05142735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 2000 mg (4 x 500-mg tablets) every morning
Study NCT05142735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 placebo tablets every morning
Study NCT04660747 — intervention group
Intervention type: DRUG
Intervention: Oral anticoagulant
Description: Direct oral anticoagulants or vitamin K antagonists. Please note that the study is fully observational. The choice of anticoagulant type and duration of treatment are left at the discretion of the treating physicians and patients. No treatment, intervention, or examinations are imposed on patients in the context of this study.
Study NCT06559254 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
Study NCT06559254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation by applying weak current through electrode. It can archive excitation by anode stimulation or inhibition by stimulating cathode. By inducing modification of membrane polarisation, it can modulate cerebral excitability. Literature suggested anode tDCS over the dorsolateral prefrontal cortex (DLPFC) improved cognitive function, in terms of responding faster and more accurate in cognitive tasks. tDCS was well tolerated and accepted by participants.
Study NCT05748535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation
Description: First of all, the application will be explained to the participants and a signed consent form for the application will be obtained from the individuals. Groups; It will be in the form of Right Ear Stimulation, Left Ear Stimulation and Bilateral Ear Stimulation group. Non-invasive auricular vagus nerve stimulation will be applied to all participants with a VAGUSTIM device, biphasic, frequency 10 Hz, pulse width 300 μs in Modulation mode, and current intensity for 20 minutes for 10 sessions, keeping the current constant at the point where the participant feels the current comfortably. Before and after each application, pulse variability (rmssd, LF/HF, pNN50, LF, HF) and blood pressure measurements will be taken from both the right index finger and left index finger. Before the first session and after the 10th session, pain level will be evaluated with the Numerical Pain Rating Scale, and disability level related to headache will be evaluated with the Headache Impact Test.
Study NCT05115357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecto-Intercostal Fascial Block
Description: A high-frequency (7-12 Mhz) linear ultrasound transducer will be placed approximately 2 cm lateral to sternal edge in the 4th or 5th intercostal space. A 22-gauge, 50-mm needle will be inserted in-plane under ultrasound guidance. The needle will be advanced through the pectoralis major muscle, and the drug will be deposited in the pecto-intercostal fascial plane located between the pectoralis major muscle and the external intercostal muscles. The separation of the fascial plane and the spread of the drug could be observed on the ultrasound image .The procedure will be repeated on the other side of sternotomy to achieve bilateral blockade.
Study NCT05115357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Thoracis Muscle Plane Block
Description: The ultrasound probe will be placed in the longitudinal plane 1 cm lateral to the sterna border. the T4-T5 intercostal space will be identified under US. A parasternal sagittal view of the internal intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib will be visualized above the pleura. A 22-gauge, 50-mm needle will be inserted inplane until the tip of the needle is located in the transversus thoracis muscle plane between the internal intercostal and transversus thoracis muscles . After excluding intravascular and intrapleural placement, local anesthetic will be administered in 5mL aliquots with intermittent aspiration.
Study NCT04079088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT04079088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Administered as specified in the treatment arm.
Study NCT04079088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.
Study NCT04079088 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta1
Description: Stable dose as prescribed by the physician.
Study NCT04079088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.
Study NCT04079088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glatiramer acetate
Description: Stable dose as prescribed by the physician.
Study NCT04766853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml
Study NCT04766853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 5mg/ml
Study NCT04766853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Hyaluronic Acid 20mg/2ml
Study NCT05087030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGB-14-P
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.